{"id":"NCT03106987","sponsor":"AstraZeneca","briefTitle":"A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.","officialTitle":"A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-08","primaryCompletion":"2021-02-15","completion":"2022-02-17","firstPosted":"2017-04-11","resultsPosted":"2022-04-19","lastUpdate":"2022-10-07"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epithelial Ovarian Cancer"],"interventions":[{"type":"DRUG","name":"Active Comparator: Olaparib tablets","otherNames":["Olaparib tablets"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active Comparator: Olaparib","type":"EXPERIMENTAL"},{"label":"Placebo Comparator: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer)","primaryOutcome":{"measure":"Efficacy: Progression-free Survival (PFS)","timeFrame":"At randomization visit and at every 12 weeks (+/- 7 days) until objective radiological disease progression as determined by the investigator or other discontinuation criteria are met (assessed upto 3.8 years)","effectByArm":[{"arm":"Olaparib (BRCA1/2 +ve)","deltaMin":4.3,"sd":null},{"arm":"Placebo (BRCA1/2 +ve)","deltaMin":2.8,"sd":null},{"arm":"Olaparib (BRCA1/2 -ve)","deltaMin":5.3,"sd":null},{"arm":"Placebo (BRCA1/2 -ve)","deltaMin":2.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0220"},{"comp":"OG002 vs OG003","p":"0.0023"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":3},"locations":{"siteCount":82,"countries":["Belgium","Canada","Denmark","France","Germany","Israel","Italy","Norway","Poland","Spain","United Kingdom"]},"refs":{"pmids":["37797734"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00014&amp;attachmentIdentifier=f6e77aa1-b549-4872-a12f-5806c419b5dd&amp;fileName=AZ_OreO_232703_D816C00014_Final_Draft_Statistical_Analysis_Plan_to_Client_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00014&amp;attachmentIdentifier=59e6cde4-5803-420a-a945-6ad185f88ce7&amp;fileName=AZ_OreO_232703_d0816c00014_Final_draft_Protocol_to_Client_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00014&amp;attachmentIdentifier=2d40e99c-1cef-45f6-bb42-9730f35cb860&amp;fileName=AZ_OreO_232703_d0816c00014_CSR_synopsis_Final_Draft_to_Client_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":74},"commonTop":["Nausea","Asthenia","Fatigue","Anaemia","Abdominal pain"]}}